Executive Summary

Lumvoa (veligrotug-vvze) is the second drug specifically approved by FDA for thyroid eye disease, establishing direct branded competition in a market created by Tepezza (teprotumumab-trbw). Lumvoa's approved five-infusion course is shorter than the current eight-infusion Tepezza course, and its pivotal program includes separate placebo-controlled phase 3 studies in active and chronic disease.

The approval package is more informative than the topline efficacy results. FDA accepted the five-infusion 10 mg/kg regimen after encouraging additional dose-ranging work, identified a large discrepancy between clinical and imaging-based estimates of chronic-disease durability, required revision of the reported antidrug-antibody incidence because of assay limitations, and evaluated a severe immune thrombocytopenia case that remained confounded by underlying autoimmune disease.

Commercially, Lumvoa enters a validated market rather than a greenfield category. Tepezza generated approximately $1.9 billion in global sales in 2025 and continued to grow before Lumvoa launched. The near-term competitive field is also moving quickly: a thyroid eye disease indication for satralizumab is under FDA priority review, while subcutaneous teprotumumab and elegrobart programs could reduce dependence on infusion centers if approved. Lumvoa therefore has a practical convenience advantage today, but the durability of that advantage is not assured.

Approval and Regulatory Path

The U.S. Food and Drug Administration (FDA) approved Biologics License Application (BLA) 761530 for veligrotug-vvze on June 26, 2026. The product is an insulin-like growth factor-1 receptor (IGF-1R) inhibitor indicated for treatment of thyroid eye disease (TED) regardless of disease activity or duration. The recommended regimen is 10 mg/kg by intravenous (IV) infusion every three weeks for five total infusions. The first infusion is administered over 45 minutes, and subsequent infusions may be administered over a minimum of 30 minutes if the preceding infusion was tolerated. 12

The molecule has an unusual development history. FDA's clinical review states that veligrotug has the same amino acid sequence as the humanized antibody AVE1642, which was created by ImmunoGen and initially developed by Sanofi-Aventis in oncology. That oncology program was discontinued for lack of efficacy. Viridian later licensed rights to develop the molecule for TED, making the approved program a therapeutic repositioning of an antibody whose earlier clinical development had targeted a different disease setting. 3

Regulatory interactions show that the pivotal regimen was not accepted without discussion. At the March 2023 End-of-Phase 2 meeting, FDA encouraged additional dose-ranging work but did not object to 10 mg/kg for the pivotal program. In June 2023, FDA agreed that eliminating a planned eight-infusion arm was acceptable, considered the proposed primary efficacy endpoint suitable to support a BLA, and asked that durability be assessed at least 24 weeks after the final infusion. In July 2024, FDA disagreed with a proposed change to the handling of missing data in an ongoing study and requested appropriate imputation, including use of magnetic resonance imaging or computed tomography information and a tipping-point analysis; the sponsor did not proceed with that amendment. 3

FDA granted Breakthrough Therapy Designation (BTD) on May 6, 2025. The clinical review records lower treatment burden, faster proptosis response, and improved diplopia response compared with Tepezza as the basis for the designation. That regulatory assessment should not be read as a randomized superiority claim: the pivotal Lumvoa studies were placebo-controlled, and the approved label does not contain a head-to-head efficacy claim against Tepezza. 32

The application was not referred to an FDA advisory committee because the agency concluded that it did not raise significant public-health questions about the biologic's role in treatment. FDA also waived the pediatric study requirement because the necessary studies were considered impossible or highly impracticable due to low prevalence. 1

Pivotal Evidence Across Active and Chronic Disease

The approval is supported by two randomized, double-masked, placebo-controlled phase 3 trials. Study 1 enrolled 113 patients with active TED, defined by disease onset within 15 months and a Clinical Activity Score (CAS) of at least 3. Study 2 enrolled 188 patients with chronic TED, defined by disease onset more than 15 months earlier and allowing a CAS from 0 to 7. Patients received five infusions of veligrotug-vvze 10 mg/kg or placebo every three weeks. 2

The publicly confirmed Lumvoa development and approval pathway can also be explored in Regulatory Designer, which maps disclosed clinical and regulatory milestones across the program.

The primary endpoint in both studies was the Week 15 proptosis responder rate, defined as at least a 2 mm reduction from baseline in the study eye without at least a 2 mm worsening in the fellow eye. FDA's clinical review described a 2 mm reduction as clinically meaningful. In active disease, the responder rate was 70% with Lumvoa and 5% with placebo, an estimated treatment difference of 65 percentage points. In chronic disease, the responder rate was 57% and 8%, respectively, an estimated difference of 49 percentage points. 23

Diplopia results add clinically relevant context beyond proptosis. Among patients with diplopia at baseline, the Week 15 diplopia responder rate in active disease was 59% with Lumvoa and 20% with placebo, while complete diplopia resolution occurred in 49% and 12%, respectively. In chronic disease, diplopia response was 56% versus 25%, and complete resolution was 32% versus 14%. These are placebo-controlled results and should not be interpreted as comparative estimates against another approved TED therapy. 2

The label reports improvement in mean proptosis as early as three weeks in both studies. FDA's clinical review describes a different response pattern by disease stage: improvement in active disease appeared to plateau earlier, while the chronic-disease response was more gradual and continued to increase across successive infusions. That pattern supports the broad approved indication but also makes longer-term durability particularly relevant in the chronic population. 23

Dose Selection and Regimen Development

The clinical pharmacology review shows why dose selection deserves more attention than a simple statement that 10 mg/kg was carried forward. Early dose-ranging evidence was based on small exploratory cohorts. After two infusions, the Week 6 proptosis responder rate in active TED was 83.3% at 10 mg/kg, compared with 66.7% at 3 mg/kg and 66.7% at 20 mg/kg; the review describes six patients per active-treatment dose cohort. In chronic TED, the corresponding Week 6 response was 50% at 10 mg/kg and 33% at 3 mg/kg, again in small cohorts. These data were exploratory and too small to establish precise comparative dose-response estimates. 4

Additional dose information came from Study 303, in which the Week 15 mean proptosis change was -2.21 mm with 10 mg/kg and -1.95 mm with 3 mg/kg. FDA's clinical pharmacology review concluded that the proposed 10 mg/kg every-three-week regimen was appropriate. The five-infusion course was selected in part because of the rapid onset of response and safety or tolerability considerations associated with a greater number of IGF-1R inhibitor infusions, and the regimen was subsequently tested in the phase 3 program. 43

A pharmacodynamic observation also illustrates the limits of biomarker interpretation in this program. Serum IGF-1 increased approximately five- to six-fold from baseline after 10 mg/kg dosing while remaining unchanged with placebo, but FDA stated that the clinical relevance of this change was unclear. The approved case therefore rests on clinical measures of proptosis and diplopia rather than on assigning clinical meaning to the circulating IGF-1 change. 4

Durability Looks Different by Measurement Method

The approved label provides a favorable but simplified view of persistence. Among patients who were proptosis responders at Week 15, 71% in the active-disease study and 57% in the chronic-disease study maintained the response at Week 52. FDA's clinical review, however, contains a more granular chronic-disease analysis showing that durability depended materially on how proptosis was measured. 23

In a restricted subgroup of chronic-disease patients who had an observed overall response at Week 15 and did not enter the open-label extension, 56.5% of evaluable patients remained responders at Week 52 when assessed by exophthalmometer, compared with 34.9% when assessed using magnetic resonance imaging (MRI) or computed tomography (CT). FDA's reviewer explicitly described a large discrepancy between the measurement methods and noted that exophthalmometry produced the more favorable estimate. 3

The divergence widened with follow-up. At Week 24, durability was 91.3% by exophthalmometer and 77.8% by imaging; at Week 36, it was 82.6% and 47.7%; at Week 52, it was 56.5% and 34.9%. These percentages should not be treated as whole-trial relapse rates because they come from a restricted observed-responder subset, with small and slightly different denominators by method. They do, however, show why a single clinical measurement can overstate certainty about structural persistence. 3

FDA's clinical reviewer concluded that persistence after treatment discontinuation appeared lower in chronic than active TED and stated that the data favored treatment earlier in the disease course when possible. That observation does not narrow the approved indication, which remains TED regardless of activity or duration, but it is relevant to treatment sequencing and to future studies of retreatment or sustained response. 32

Immunogenicity and Thrombocytopenia

FDA's immunogenicity review identified a defined analytical limitation. Antidrug antibodies (ADAs) are antibodies that develop against the therapeutic protein, while neutralizing antibodies (NAbs) are a subset capable of interfering with biological activity. Product-quality reviewers found inadequate drug tolerance in both the ADA and NAb assays, limiting detection of low- to mid-titer ADAs during treatment and of NAbs during treatment and much of the washout period. 3

The analytical issue changed the reported incidence. The applicant initially reported treatment-emergent ADA incidence of 16.1%, but FDA required reclassification to 20.0%. The NAb results were considered uninformative. The review states that the true incidence of low- to mid-titer ADAs and NAbs remained unknown, as did whether such responses could affect pharmacokinetics (PK), pharmacodynamics (PD), safety, or efficacy, particularly with repeat treatment. 3

The final label reports treatment-emergent ADAs in 20% of evaluated patients, 58 of 290, and states that no apparent relationship was observed between ADA development and PK, safety, or effectiveness. It also cautions that observed antibody incidence depends heavily on assay sensitivity and specificity. The practical interpretation is therefore narrower than saying immunogenicity was absent: clinically important effects were not apparent in the available dataset, but low- and mid-titer responses were incompletely characterized. 23

A separate FDA hematology consultation evaluated one Grade 4 case of immune thrombocytopenia (ITP) in the chronic-disease trial. The patient's platelet count declined from 190 x 10^9/L at baseline to 86 x 10^9/L by the fifth infusion and later to 17 x 10^9/L, leading to an ITP diagnosis. FDA considered Graves disease an important confounder and did not classify ITP as an adverse reaction to veligrotug at that time, but the severity supported continued awareness and pharmacovigilance. The final label notes that ITP was reported in one patient. 52

Safety and Risk Management

Lumvoa's labeled warnings and precautions include infusion reactions, inflammatory bowel disease (IBD), hyperglycemia, and hearing impairment including hearing loss, which may be permanent. In the pooled placebo-controlled safety dataset, muscle spasms occurred in 40% of Lumvoa-treated patients versus 7% with placebo, hearing impairment in 15% versus 6%, and hyperglycemia in 13% versus 5%. Headache, fatigue, diarrhea, ear discomfort, nausea, nasopharyngitis, and infusion reactions were also among the adverse reactions reported in the label. 2

The trials' eligibility criteria matter when extrapolating those safety results. The pivotal studies excluded patients with abnormal baseline audiometry or a history of significant ear pathology, relevant ear surgery, or hearing loss, and they excluded patients with biopsy-proven or clinical evidence of IBD. The approved label has no contraindications but instructs clinicians to monitor for IBD, glycemic abnormalities, and hearing impairment. 2

FDA's Division of Risk Management concluded that a Risk Evaluation and Mitigation Strategy (REMS) was not necessary. The review identified IBD, hyperglycemia, and hearing impairment as known risks of the IGF-1R inhibitor class and concluded that labeling was sufficient for risk communication at approval. This was not a finding that the risks were negligible; it was a determination that additional REMS controls were not required. 6

Safety percentages for Lumvoa and Tepezza should not be compared as if they arose from a randomized head-to-head trial. Both labels explicitly note that adverse-event rates observed in one product's clinical studies cannot be directly compared with rates in another product's studies because populations, designs, ascertainment, and exposure differ. 27

Product Quality Review Adds Manufacturing Context

FDA's Integrated Quality Assessment recommended approval and concluded that the manufacturing control strategy was adequately established. Potency is controlled with assays that measure IGF-1R binding and inhibition of IGF-1-induced receptor autophosphorylation, connecting product-quality testing to the intended mechanism of action. 8

The review also documents an inspection approach that is easy to misinterpret without context. For the drug-substance manufacturing site operated by WuXi Biologics in Jiangsu, China, FDA used a records request in lieu of an on-site inspection and identified no approvability issue. Inspection of the drug-product site was waived. FDA's quality reviewers also concluded that lot-to-lot variability did not present a concern and that the overall control strategy supported approval. 8

For regulatory strategy, the significance is procedural rather than cautionary. The use of records in lieu of an on-site inspection was part of FDA's facility-assessment process and did not result in a manufacturing deficiency that blocked approval. The quality package therefore provides an example of a biologic approval proceeding with alternative inspection mechanisms when FDA considered the available information adequate. 8

The TED Market Is Broader Than Two Approved Drugs

As of August 19, 2026, Lumvoa and Tepezza are the two FDA-approved drug products specifically indicated for TED in the United States. That does not mean they are the only treatments used in TED. Management also includes glucocorticoids, other immunomodulatory drugs used off label, orbital radiotherapy, surgical decompression, strabismus surgery, eyelid surgery, and supportive treatment, with selection driven by disease activity, severity, phenotype, visual threat, treatment goals, access, and regional practice. 27910

The treatment landscape is especially sensitive to guideline timing and geography. The 2021 European Group on Graves' Orbitopathy guideline recommends intravenous methylprednisolone combined with mycophenolate sodium as first-line treatment for many patients with active moderate-to-severe disease, with higher-dose intravenous glucocorticoid monotherapy for more severe presentations and several pharmacologic or radiotherapy options in second line. The 2022 American Thyroid Association and European Thyroid Association consensus gives teprotumumab a more prominent role for active moderate-to-severe disease with significant proptosis or diplopia and favors intravenous glucocorticoids when inflammatory activity is prominent without substantial proptosis or diplopia. 109

Those documents predate Lumvoa and should not be read as current recommendations ranking Lumvoa against Tepezza. They are most useful for showing the clinical alternatives against which a new TED biologic competes. They also show why the commercial market is larger than a two-product biologic comparison: a patient who is eligible for targeted therapy may instead receive immunosuppression, radiotherapy, surgery, observation, or staged combinations depending on presentation and local practice. 1092

For sight-threatening TED, treatment remains qualitatively different from routine control of proptosis or diplopia. EUGOGO recommends high-dose intravenous methylprednisolone for dysthyroid optic neuropathy, with urgent orbital decompression when response is absent or inadequate. In inactive disease with persistent structural consequences, rehabilitative orbital decompression, strabismus surgery, and eyelid surgery remain important treatment modalities even in an era of targeted biologics. 10

Lumvoa Versus Tepezza in the Current Approved Market

The most immediate labeled differentiation between the two approved TED biologics is treatment burden. Lumvoa is administered at 10 mg/kg every three weeks for five IV infusions. Tepezza is administered as 10 mg/kg for the first infusion followed by 20 mg/kg every three weeks for seven additional infusions, for eight total infusions. Both products carry broad TED indications regardless of disease activity or duration. 27

The difference extends to infusion duration. Lumvoa's first infusion is 45 minutes and subsequent infusions may be administered over at least 30 minutes if tolerated. Tepezza's first two infusions are administered over at least 90 minutes, with later infusions reducible to 60 minutes if tolerated. Using only those minimum labeled administration times, a fully accelerated Lumvoa course totals 165 minutes of drug infusion versus 540 minutes for Tepezza, a difference of 375 minutes, or 6 hours 15 minutes. This calculation excludes preparation, observation, travel, scheduling, and other site-of-care time. 27

Efficacy should not be compared by placing the two labels' responder percentages side by side as though they came from one trial. Lumvoa's pivotal studies assessed the primary proptosis endpoint at Week 15 and included separate active and chronic populations. Tepezza's original pivotal placebo-controlled studies assessed proptosis at Week 24 in active disease. Differences in population, endpoint timing, treatment exposure, and study design prevent a valid indirect claim of superior efficacy from the label tables alone. 27

The same caution applies to safety. Both labels include warnings for infusion reactions, IBD, hyperglycemia, and hearing impairment, but cross-trial adverse-event percentages are not a substitute for comparative safety evidence. Lumvoa's strongest current label-based competitive distinction is therefore operational: fewer infusions and less labeled infusion time, coupled with placebo-controlled efficacy evidence in both active and chronic disease. 27

Commercial Assessment: Share Capture in a Validated Market

The commercial opportunity is validated by Tepezza's existing franchise. Amgen reported $1.903 billion in global Tepezza sales for full-year 2025, including $1.758 billion in the United States and $145 million outside the United States. In the second quarter of 2026, before Lumvoa's late-June approval could meaningfully affect market share, Tepezza generated $576 million in global sales, up 14% year over year, with Amgen attributing the increase primarily to higher net selling price and volume growth. 1112

That revenue base changes the nature of Lumvoa's launch. Viridian is not trying to prove that physicians and payers will fund a high-value disease-specific TED biologic from scratch; it is trying to capture share and potentially expand treatment within an already established category. Reuters reported that Viridian expected course-of-treatment pricing to be at parity with the existing approved IGF-1R therapy, indicating that the initial strategy was not framed as a list-price discount. 1311

Early launch disclosures are activity indicators rather than commercial outcomes. Viridian reported that the first Lumvoa doses were administered in July 2026 and that, as of July 31, its field team had engaged 95% of approximately 2,000 core prescribing physicians. The company also said payer-coverage efforts were on track. Because the second quarter ended June 30 and commercial dosing began in July, the company's second-quarter results do not provide a meaningful Lumvoa product-sales baseline. 14

The strongest near-term commercial case is therefore based on treatment logistics rather than demonstrated price or efficacy superiority. Five infusions instead of eight can reduce patient visits, infusion-center chair time, and labeled administration time. Separate controlled evidence in active and chronic TED may also simplify the clinical evidence discussion across disease stages. Against those advantages, Tepezza has an established revenue base and a multi-year position in the market. This is a commercial inference from the approved labels and reported sales and launch metrics, not an observed market-share result. 271114

The FDA review also identifies factors that could matter commercially after launch. The chronic-disease durability discrepancy raises a question about how sustained benefit will be perceived if retreatment becomes common, while incomplete low- and mid-titer immunogenicity characterization leaves uncertainty around repeated exposure. Neither issue prevented approval, and neither establishes a commercial problem today, but both are relevant to real-world persistence, retreatment patterns, and future payer evidence requirements. 3

A quantitative Lumvoa revenue forecast would be premature on the currently public evidence. Viridian had only just begun commercial dosing by its most recent reported update, so there is not yet a sufficiently mature product-revenue series from which to estimate durable market share, net price, discontinuation, or retreatment. The more defensible near-term commercial indicators are payer coverage, time to treatment, new patient starts, prescriber breadth, share within infusion centers, and the first several quarters of recognized product revenue. 1413

Future Outlook: Convenience and Mechanism Both Matter

The most immediate potential change to the U.S. competitive set is satralizumab. Genentech announced on June 29, 2026 that FDA had accepted a supplemental BLA and granted Priority Review for Enspryng (satralizumab) in TED, based on two randomized, placebo-controlled phase 3 SatraGO studies in moderate-to-severe disease. FDA action is expected by October 15, 2026. Enspryng is already an FDA-approved product in another indication, but its use for TED remains under review and is not FDA-approved for TED as of August 19, 2026. 15

The route-of-administration race is also important. Amgen reported positive phase 3 topline results for an investigational subcutaneous (SC) formulation of teprotumumab delivered by an on-body injector in moderate-to-severe active TED. At Week 24, the proptosis responder rate was 76.7% with SC teprotumumab and 19.6% with placebo, and mean proptosis change was -3.17 mm and -0.80 mm, respectively. The SC formulation is investigational and is not part of the current FDA-approved Tepezza IV label. 167

Viridian is developing elegrobart, a separate investigational SC IGF-1R antibody. In the company-reported REVEAL-1 phase 3 study in active TED, Week 24 proptosis responder rates were 54% with every-four-week dosing, 63% with every-eight-week dosing, and 18% with placebo. In REVEAL-2 chronic TED, the corresponding rates were 50%, 54%, and 15%. Viridian states that a BLA submission is planned for the first quarter of 2027 and is developing a low-volume autoinjector intended to support at-home administration if approved. These results are sponsor-reported topline data and have not yet resulted in an FDA approval. 171814

Not every alternative mechanism has translated into late-stage success. Immunovant reported in April 2026 that two phase 3 studies of the neonatal Fc receptor-targeting antibody batoclimab in active moderate-to-severe TED failed their primary Week 24 proptosis-response endpoints. Those failures reduce the immediate competitive relevance of that specific program, but they do not establish that the entire mechanism class is ineffective in TED. 19

Oral therapy remains conceptually important because it could remove infusion or injection burden altogether. Sling Therapeutics reported in January 2025 that the oral small-molecule IGF-1R inhibitor linsitinib achieved a 52% Week 24 proptosis responder rate at 150 mg twice daily in a 90-patient phase 2b/3 study, with a nominal p value of 0.01 versus placebo, and said it planned a confirmatory phase 3 study. The cited current materials do not establish a later FDA submission timeline, so its eventual regulatory position should be treated as unspecified rather than assumed. 20

Taken together, the pipeline suggests that convenience may become a temporary rather than permanent differentiator. Lumvoa currently improves on the incumbent IV regimen through fewer and shorter infusions. If at-home SC products or other non-infusion mechanisms gain approval, competitive emphasis could shift toward magnitude and durability of benefit, disease-stage coverage, hearing and metabolic safety, retreatment, payer policy, and total site-of-care economics. That is an inference from the current approved labels and disclosed development programs, not a prediction that any investigational product will be approved. 2715161718

Conclusion

Veligrotug-vvze expands the FDA-approved TED market from a single branded biologic to direct competition within the IGF-1R class. The five-infusion regimen is a tangible operational advantage, and the approval is supported by separate controlled studies in active and chronic disease. At the same time, FDA's review package shows that the program carries more nuance than its headline responder rates: chronic-disease durability depends on measurement method, immunogenicity was incompletely characterized at lower antibody titers, and a severe thrombocytopenia case remains part of the safety context despite uncertain causality.

The broader market is not simply Lumvoa versus Tepezza. Glucocorticoids, other off-label immunomodulators, radiotherapy, and surgery remain part of TED management, while multiple late-stage programs are attempting to shift therapy toward subcutaneous or alternative-mechanism treatment. Commercially, Lumvoa enters a proven market with a meaningful convenience proposition, but its long-term position will depend on payer access, physician adoption, durability and retreatment experience, and how quickly the competitive field moves away from facility-based infusion.